The diagnosis and treatment of patients with onychomycosis, bacterial and inflammatory skin diseases can be challenging. It is often stated that only about 50% of nail dystrophies are caused by fungus, so it’s important that the diagnosis of onychomycosis be confirmed by histology, culture, or advanced molecular techniques. The choice of treatment for onychomycosis has always been daunting. In which patients is it appropriate to use oral antifungals, topical drugs, or a combination of the two? What role do in-office dispensed over the counter (OTC) agents play; if any? To complicate matters there is now emerging evidence that drug resistant dermatophytes are becoming an emerging clinical problem. Left untreated, onychomycosis can cause wounds, cellulitis, secondary bacterial infection, pain, and difficulty ambulating, especially in patients with underlying co-morbidities. These secondary bacterial infections can also be difficult to treat. Increasing rates of skin and skin structure infection caused by resistant bacteria, such as MRSA can complicate patient management.
The purpose of this free half day virtual conference will be to provide updates on the evolving understanding of the epidemiology and pathophysiology of nail and skin structure infections and inflammatory processes. New techniques in diagnosis will be discussed. The problem of antifungal resistant dermatophytes will be reviewed. Treatment best practices in adults and children with onychomycosis using new evidence-based treatment guidelines will be explained. This in turn will help providers to integrate evidence-based strategies and procedures into their clinical practice to treat fungal and bacterial nail and skin structure infections and inflammatory conditions in these complicated patients.